Cixutumumab - Eli Lilly

Drug Profile

Cixutumumab - Eli Lilly

Alternative Names: A12; IMC-A12; LY3012217; NSC 742460

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer ImClone Systems; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Thymoma

Most Recent Events

  • 01 May 2018 ImClone terminates a phase II trial in Colorectal cancer (Combination therapy, Metastatic disease) due to business reasons in USA (IV) (NCT00845039)
  • 01 Jul 2016 ImClone completes its phase II trial for Neuroendocrine tumours in (NCT00781911)
  • 30 Jun 2016 Eli Lilly completes its phase II trial for Non-small cell lung cancer in US, Argentina, Brazil, Canada, EU, Israel and Turkey (NCT01232452)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top